Arcus Biosciences’ casdatifan shows 35% response rate, 15.1-month PFS in metastatic ccRCC in ARC-20 data published in Nature
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $258.00M | $117.00M | $112.00M | $383.00M | $78.00M | $15.00M | $8.35M | $1.41M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $258.00M | $117.00M | $112.00M | $383.00M | $78.00M | $15.00M | $8.35M | $1.41M |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | $588.00M | $457.00M | $392.00M | $329.00M | $202.00M | $103.71M | $63.21M | $54.85M |
| Operating Income | $-330.00M | $-340.00M | $-280.00M | $54.00M | $-124.00M | $-88.71M | $-54.86M | $-53.44M |
| Operating Margin | -127.91% | -290.60% | -250.00% | 14.10% | -158.97% | -591.39% | -656.76% | -3782.09% |
| Net Income | $-283.00M | $-307.00M | $-267.00M | $53.00M | $-123.00M | $-84.71M | $-49.59M | $-53.08M |
| Net Margin | -109.69% | -262.39% | -238.39% | 13.84% | -157.69% | -564.73% | -593.73% | -3756.69% |
| EPS (Basic) | $-3.14 | $-4.15 | $-3.71 | $0.76 | $-2.13 | $-1.73 | $-1.43 | $-2.16 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |